1. Lipe S, et al: A comparison of the effects of endralazine and hydralazine on isolated human arteries and veins [abstr]. Clin Exp Pharmacol Physiol 7:685, 1980.
2. Salzmann R, et al: Pharmakologische Wirkungen des antihypertensivums 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido (4, 3-c) Pyridazin (BQ 22–708, endralazin). Arzneimittelforsch 29:1843, 1979.
3. Quyyumi AA, et al: Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Am J Cardiol 51:1353, 1983.
4. Quyyumi AA, et al: Long-term beneficial effects of endralazine, a new arteriolar vasodilator, at rest and during exercise capacity in chronic congestive heart failure. Am J Cardiol 54:1020, 1984.
5. Elliott HL, et al: The pharmacodynamics of the vasodilator, endralazine, in normotensive subjects and essential hypertensives. J Cardiovasc Pharmacol 1983 (in press).